logo
The Old-School Ab Routine That Built Classic Physiques Without Crunches

The Old-School Ab Routine That Built Classic Physiques Without Crunches

Yahoo19-07-2025
Flip through any health and fitness magazine from the last few decades and you'll find no shortage of ab exercises promising that coveted six-pack—crunches, sit-ups, planks, you name it. And while those moves all have their place in a solid core routine, they might not cut it if you're chasing the kind of definition seen on old-school bodybuilders.
Hanging leg raises and Roman chair sit-ups, on the other hand, were staples in golden-era routines for a reason. These exercises demand a greater range of motion and target far more than just the upper abs. Unlike crunches, which primarily hit the top of the rectus abdominis, these moves engage the lower abs, hip flexors, obliques, and deep stabilizing muscles. That makes them more effective not just for aesthetics, but also for building serious, functional core strength.
"These two moves train the core differently compared to modern ab exercises like crunches or cable crunches because they allow a greater range of motion," said NYC-based Life Time Trainer Joseph David. "A deeper stretch and contraction will lead to amazing results."Roman Chair Situps
How to Do It
On a roman chair or glute-ham developer, sit facing the foot support with your lower legs secured under the leg pads and your butt against the larger padded support.
Lean back, keeping your core engaged and your back straight, and then return to the starting position by flexing your hips.
Avoid arching your back excessively or using momentum—it's all about control.
Hanging Leg Raises
How to Do It
Hang from a pullup bar with hands slightly wider than shoulder width and palms facing forward, to start.
Set your lats (pull your shoulder blades down your back) and engage your core to raise your knees to your chest.
Lower with control to the hanging position.
That's 1 rep.How to Add Resistance in Core Training
As with any exercise, building muscle requires progressive overload—that means gradually increasing the challenge by adding resistance, upping your reps, using more weight, or shortening your rest periods.
"Progressive resistance can also help eliminate plateaus by preventing your body from adapting to a certain resistance," David says. "Keep your core guessing."
What Old-School Lifters Got Right About Core Training
Old-school lifters didn't rely on endless crunches, yet they still built rock-solid abs. So, how did they sculpt those classic six-packs? According to David, it starts with intention—you can turn almost every movement into a core workout if you engage the right muscles.
"Keeping your core engaged in any lift or workout sequence will protect your spine, improve your posture, and overall fitness," David says. "There's more to core than having a sculpted physique. A strong core is injury prevention!"
The Old-School Ab Routine That Built Classic Physiques Without Crunches first appeared on Men's Journal on Jul 18, 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition
Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition

Yahoo

time28 minutes ago

  • Yahoo

Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition

On Tuesday, the eye care company Alcon Plc (NYSE:ALC) agreed to acquire STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the implantable collamer lens (ICL). The acquisition includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism. Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) and a 51% premium to the closing price of STAAR common stock on August 4, transaction represents a total equity value of approximately $1.5 billion. Alcon intends to finance the transaction by issuing short- and long-term credit facilities. The transaction is anticipated to close in approximately six to 12 months and is expected to be accretive to earnings in year two. 'With the number of high myopes rising globally, the acquisition of STAAR enhances our ability to offer a leading surgical vision correction solution for those who are not ideal candidates for other refractive surgeries such as LASIK,' said David Endicott, CEO of Alcon. An estimated 50% of the world will be myopic by 2050, and today, nearly 500 million people are considered high myopes. The EVO family of ICLs are implanted between the iris (the colored part of the eye) and the natural crystalline lens during a procedure that does not remove corneal tissue. This move follows Alcon's recent announcement in July regarding its intention to acquire LumiThera, Inc. and its Photobiomodulation (PBM) Device for dry age-related macular degeneration (AMD). Data from the LIGHTSITE I, II, and III clinical trials consistently showed that PBM treatments provide visual acuity improvement with no treatment-related serious adverse events reported. PBM received FDA de novo market authorization in November 2024 and CE Mark in November 2018. PBM is available in Europe, Latin America, Singapore, the U.K., and the U.S. The transaction does not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices, which will be separated and spun off to LumiThera's shareholders before Alcon's acquisition and will continue to be marketed and sold by the LumiThera spin-off. Alcon and LumiThera anticipate the acquisition to be completed in the third quarter of 2025. Price Action: ALC stock is trading lower by 1.17% to $86.79 premarket, and STAA stock is trading higher by 44.9% to $26.78 at last check Tuesday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? STAAR SURGICAL (STAA): Free Stock Analysis Report This article Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Digital health company eMed taps former X boss Linda Yaccarino as CEO
Digital health company eMed taps former X boss Linda Yaccarino as CEO

Yahoo

timean hour ago

  • Yahoo

Digital health company eMed taps former X boss Linda Yaccarino as CEO

(Reuters) - Digital health platform eMed Population Health said on Tuesday it has appointed Linda Yaccarino, the former CEO of social media site X, as its chief executive officer. The online weight management company's digital platform provides at-home diagnostics, proctor-led screenings, physician-guided prescribing for patients with obesity and type 2 diabetes. Yaccarino, one of Elon Musk's top deputies, stepped down from her role at the social media site in July, in a surprise move just months after the platform was acquired by the billionaire's AI startup, xAI.

Annual spending on specialty drugs continues to increase but at a slower pace than prior years, driven in part by biosimilar adoption.
Annual spending on specialty drugs continues to increase but at a slower pace than prior years, driven in part by biosimilar adoption.

Yahoo

timean hour ago

  • Yahoo

Annual spending on specialty drugs continues to increase but at a slower pace than prior years, driven in part by biosimilar adoption.

DALLAS, August 05, 2025--(BUSINESS WIRE)--Pharmaceutical Strategies Group ("PSG"), an EPIC company, released the Artemetrx State of Specialty Spend and Trend report. This annual report provides a comprehensive analysis based on real world data of utilization of specialty medications across both pharmacy and medical benefits. This year's report revealed per member per year specialty drug cost increased from $1,333 in 2023 to $1,641 in 2024. However, specialty drug trend decreased to 9.6% in 2024 on a gross cost basis, a decline from 14.4% in 2023. Notably, cost per claim was meaningfully less of a contributor to trend this year versus recent years. "The data reveals a compelling story regarding what is happening with specialty drugs. Overall costs continue to increase for healthcare payers, but what is driving that cost is changing," stated Morgan Lee, PhD, Senior Director of Research & Strategy at PSG. "Adoption of Humira biosimilars helped pull specialty trend down this year, which is evident throughout the report," Lee added. While Humira continued its multi-year reign as the top specialty drug in terms of overall spend, this popular drug experienced negative utilization and cost per claim trends driven by the adoption of biosimilars. "In 2024, we saw the benefit to healthcare payers of Humira biosimilars as PBMs shifted strategies to take advantage of competition in the market," observed Renee Rayburg, RPh, Vice President of Clinical Strategy at PSG. "We expect to see faster adoption of Stelara biosimilars, which entered the market early this year. However, we're also seeing a push to move patients from these drugs to other brand drugs that do not have biosimilar competition." The Artemetrx State of Specialty Spend and Trend Report reflects PSG's commitment to providing data-driven insights regarding the management of and opportunities to optimize specialty medications. The complimentary report can be downloaded here. Additional findings covered in the report include: The percentage of members utilizing a specialty drug increased (4.7%), while average specialty claims per utilizer was steady (5.9) The shift of specialty drug spending to the pharmacy benefit continued The top three categories for specialty drug spend remained unchanged: Inflammatory Disorder, Oncology, Multiple Sclerosis PSG will host a webinar on August 13th, at 1:00 ET to discuss how this report can shape a roadmap for proactive specialty spend control. Registration is available online. About Pharmaceutical Strategies Group (PSG) Pharmaceutical Strategies Group, an EPIC company, relentlessly advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG is an independent consultant, empowering healthcare payers to optimize their pharmacy program. As a strategic partner, PSG helps clients by providing industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. About Artemetrx® Artemetrx is a proprietary SaaS platform developed by Pharmaceutical Strategies Group, an EPIC company. As a revolutionary technology solution integrating pharmacy and medical claims data for specialty drug cost management, Artemetrx provides market-leading specialty drug insights to payers. It delivers unparalleled intelligence and line-of-sight into serious challenges perpetuating out-of-control drug costs and compromised patient outcomes. PSG's innovative drug management solutions, including Artemetrx, deliver actionable insights with exceptional financial and clinical value. PSG functions as a strategic partner through industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. View source version on Contacts Artemetrx Business Development Travis Media Contact Gregory FCA For Pharmaceutical Strategies GroupKara Lesterepic@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store